Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-25-000070
Filing Date
2025-08-06
Accepted
2025-08-06 16:06:31
Documents
69
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20250630.htm   iXBRL 10-Q 1307043
2 EX-10.1 exhibit10110-qxq22025.htm EX-10.1 17181
3 EX-31.1 exhibit311q22025.htm EX-31.1 17233
4 EX-31.2 exhibit312q22025.htm EX-31.2 17114
5 EX-32.1 exhibit321q22025.htm EX-32.1 9845
  Complete submission text file 0001664710-25-000070.txt   5883297

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20250630.xsd EX-101.SCH 40065
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20250630_cal.xml EX-101.CAL 52308
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20250630_def.xml EX-101.DEF 246961
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20250630_lab.xml EX-101.LAB 540254
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20250630_pre.xml EX-101.PRE 379857
72 EXTRACTED XBRL INSTANCE DOCUMENT kros-20250630_htm.xml XML 592001
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 251189507
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)